Abstract | BACKGROUND AND AIM: METHODS: In a 1:1:1 cross-sectional study, we evaluated LV function by speckle-tracking echocardiography in 34 ADPKD patients from one ALADIN-trial center and in 34 age- and gender-matched healthy controls and 34 equally-matched renal controls with non-cystic chronic kidney disease. Changes in LV function were compared in the 16 and 18 ADPKD patients originally randomized to 3 year-treatment with octreotide-LAR or placebo, respectively. RESULTS: LV twist and untwisting rates were lower in ADPKD patients that in healthy or renal controls (6.1 ± 2.6° vs. 11.1 ± 2.1° and 10.2 ± 3.7°; -49.5 ± 18.1°/s vs. -79.8 ± 12.2°/s and -84.3 ± 25.9°/s, respectively, all p < 0.001). The correlation between LV mass or diastolic BP and untwisting rate was positive in ADPKD patients (r = 0.38, p = 0.025 and r = 0.44, p = 0.011, respectively), not significant in healthy controls and negative in renal controls (r = -0.38; p = 0.023 and r = -0.40, p = 0.012, respectively. LV untwisting rate improved from -49.9 ± 18.6°/s to -70.3 ± 27.5°/s with octreotide-LAR, but did not change with placebo (p = 0.027 for treatment effect). At adjusted linear regression analysis, octreotide-LAR therapy emerged as the only independent predictor of untwisting rate improvement at final visit [beta coefficient -0.504 (95% CI -46.905--6.367), p = 0.014]. CONCLUSIONS: In ADPKD patients LV function is early impaired. Somatostatin-analogue therapy might help in preventing or ameliorating LV dysfunction in this population. Clinical Trial Registration http://www.clinicaltrials.gov, NCT0030928.
|
Authors | Letizia Spinelli, Antonio Pisani, Giuseppe Giugliano, Bruno Trimarco, Eleonora Riccio, Bianca Visciano, Giuseppe Remuzzi, Piero Ruggenenti, ALADIN-Cardiovascular Study Group |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 275
Pg. 145-151
(Jan 15 2019)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 30509370
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright © 2018 Elsevier B.V. All rights reserved. |
Chemical References |
- Antineoplastic Agents, Hormonal
- Octreotide
|
Topics |
- Administration, Oral
- Adult
- Antineoplastic Agents, Hormonal
(administration & dosage)
- Cross-Sectional Studies
- Dose-Response Relationship, Drug
- Echocardiography, Doppler
- Female
- Follow-Up Studies
- Glomerular Filtration Rate
- Heart Ventricles
(diagnostic imaging, drug effects, physiopathology)
- Humans
- Male
- Middle Aged
- Octreotide
(administration & dosage)
- Polycystic Kidney, Autosomal Dominant
(complications, drug therapy, physiopathology)
- Prospective Studies
- Stroke Volume
(drug effects, physiology)
- Time Factors
- Treatment Outcome
- Ventricular Dysfunction, Left
(diagnosis, etiology, prevention & control)
- Ventricular Function, Left
(drug effects)
|